Declines in RLX and Smoore highlight the importance of rigorous regulatory risk assessment. Governments' desire to protect revenue and the abstinence-based approach of the WHO suggests growing regulatory pressure. Still, investors remain positive.

Australia's attempt to ban imports of nicotine-based vaping products highlights real obstacles to tobacco harm reduction.